BeOne Medicines (NASDAQ:ONC) Shares Gap Up - Still a Buy?

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report)'s share price gapped up before the market opened on Monday . The stock had previously closed at $247.08, but opened at $260.00. BeOne Medicines shares last traded at $257.67, with a volume of 111,639 shares.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Royal Bank Of Canada reduced their price target on BeOne Medicines from $312.00 to $311.00 and set an "outperform" rating for the company in a report on Thursday, May 8th. Sanford C. Bernstein set a $259.00 price objective on shares of BeOne Medicines in a report on Thursday, March 13th. JPMorgan Chase & Co. upped their price target on shares of BeOne Medicines from $311.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, April 21st. Guggenheim boosted their price objective on BeOne Medicines from $348.00 to $350.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. Finally, Wall Street Zen upgraded BeOne Medicines from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, BeOne Medicines has an average rating of "Buy" and a consensus price target of $319.00.

BeOne Medicines Price Performance

The firm has a 50-day simple moving average of $247.22. The company has a current ratio of 1.96, a quick ratio of 1.71 and a debt-to-equity ratio of 0.05. The company has a market cap of $27.89 billion, a P/E ratio of -68.41 and a beta of 0.30.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.12 billion. Sell-side analysts predict that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current year.

Insider Buying and Selling at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 5,127 shares of the business's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $252.77, for a total transaction of $1,295,951.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Xiaodong Wang sold 41,760 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $223.50, for a total transaction of $9,333,360.00. The disclosure for this sale can be found here. Insiders sold a total of 203,452 shares of company stock worth $51,856,379 over the last three months. Corporate insiders own 6.62% of the company's stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.